semaglutide cardiovascular and Outcomes in Obesity | NEJM Insights into semaglutide cardiovascular research:

Obesity is obviously not restricted to the US

Liraglutide reduces CNS activation in response to visual food cues only after short-term treatment in patients with type 2 diabetes

These include improvements in cardiovascular outcomes, making it particularly relevant for patients with type 2 diabetes who are at higher risk of heart disease. Such benefits have positioned semaglutide as a comprehensive metabolic therapy rather than a single-purpose drug

Unfortunately, as more people get swept into overpromising trends, as many as 400 people have claimed serious injuries including gallbladder disease, stomach paralysis, and breathing in undigested food while under anesthesia from the drugs

Extended applications Current research focuses on metabolic disease and aging

Weight Loss and Variation of Levothyroxine Requirements in hypothyroid subjects after bariatric surgery